Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspryng® (satralizumab) reduced the risk of a new ...

Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage ...

Nondisabling relapses that occur early in the course of relapsing-remitting multiple sclerosis (RRMS) signal faster accumulation of disability relative to no early relapses, new research suggests.

Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

Genentech’s Enspryng reduces risk of relapses by 68%; shows potential to become first treatment for MOGAD: South San Francisco, California Thursday, April 23, 2026, 15:00 Hrs [I ...

Clinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without metastases. One treatment strategy after orchiectomy is adjuvant chemotherapy. Little is known about the outcome of ...

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer The July 20, 2019, article ...

A bowel cancer trial using immunotherapy before surgery has shown zero relapses after nearly three years, offering hope for ...